KM-819

DRUG3 trials

Sponsors

Kainos Medicine Inc., FAScinate Therapeutics Inc.

Conditions

Multiple System AtrophyParkinson DiseaseParkinson's Disease

Phase 1

Phase I, KM-819 in Healthy Subjects for Parkinson's Disease

CompletedNCT03022799

Kainos Medicine Inc.Parkinson's Disease

Start: 2016-11-30End: 2017-11-30Updated: 2020-04-13

Phase 2

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease

Active, not recruitingNCT05670782

FAScinate Therapeutics Inc.Parkinson Disease

Start: 2022-07-19End: 2025-11-13Target: 314Updated: 2025-03-05

Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)

TerminatedNCT05695378

Kainos Medicine Inc.Multiple System Atrophy

Start: 2023-02-27End: 2024-08-19Updated: 2024-09-19